116 related articles for article (PubMed ID: 11486155)
1. Adverse drug reaction reporting.
Somberg JC
Am J Ther; 2000 Aug; 7(4):227-8. PubMed ID: 11486155
[No Abstract] [Full Text] [Related]
2. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine.
Keller WC; Bataller N; Oeller DS
J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589
[No Abstract] [Full Text] [Related]
3. FDA's role in drug product recalls.
Crawford SY
Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
[No Abstract] [Full Text] [Related]
4. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
5. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
6. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
Lexchin J
CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
[No Abstract] [Full Text] [Related]
7. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
8. A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs.
Waxman HA
Food Drug Law J; 2003; 58(3):299-312. PubMed ID: 14626231
[No Abstract] [Full Text] [Related]
9. Vioxx, radiology, and the Food and Drug Administration.
Pentecost MJ
J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
[No Abstract] [Full Text] [Related]
10. Clinical trials and public trust.
Kennedy D
Science; 2004 Dec; 306(5702):1649. PubMed ID: 15576574
[No Abstract] [Full Text] [Related]
11. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
12. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
13. Five fixes to improve drug safety. Ideas for how to prevent another Vioxx debacle.
Thygeson M
Minn Med; 2005 Dec; 88(12):36-7. PubMed ID: 16583524
[No Abstract] [Full Text] [Related]
14. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
15. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
16. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
17. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
18. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
19. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Chez RA
Obstet Gynecol; 1995 Jul; 86(1):154-5. PubMed ID: 7784014
[No Abstract] [Full Text] [Related]
20. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
